Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2016

View Archived Issues

Benitec to terminate HCV program

Novel sulfiredoxin inhibitor induces selective death of cancer cells

Lumosa Therapeutics describes novel thrombolytic agent DC-009

EMA committee recommends approval of Idelvion for hemophilia B

Innovate licenses larazotide acetate from Alba Therapeutics

Novel anti-HIV combinectin BMS-986197 may have enhanced resistance profile

Cebranopadol demonstrates significant improvements in lower backpain in phase IIb study

Siemens to release genetic assay for early detection of Zika virus

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents TLR7 agonists

Hydra Biosciences reports development of TRPC5 antagonists

FLAG-003 awarded E.U. orphan drug designation for glioma

MAA submitted for tivozanib as first-line treatment of advanced RCC

Z53 Therapeutics is launched as a novel oncology start-up

Modified version of troponin C modulates cardiac contractility in vivo

Preclinical and phase I results presented for HIV treatment/prophylaxis candidate MK-8591

Polymorphism in galectin-3 lectin domain is associated with beta-lactam allergy

Aytu BioScience and Hybridyne enter study agreement for trial using ProxiScan and ProstaScint

Pfizer initiates phase I study of PF-06801591

FDA approves Odefsey single-tablet regimen for HIV-1 infection

FDA announces new Orphan Products Natural History Grants program

Horizon Discovery and Centauri Therapeutics form Avvinity Therapeutics

Evgen cleared to begin phase II trial of SFX-01 for aneurysmal subarachnoid hemorrhage

ProStrakan signs agreement to acquire Moventig rights in Europe

FDA grants orphan drug designation to BMN-270 gene therapy for hemophilia A

New phase II trial investigates sulfatinib for thyroid cancer

First-in-human study of oral antimalarial drug SJ-733

Hikma closes acquisition of Roxane Laboratories and Boehringer Ingelheim Roxane

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...